iPharma Center

Business account of iPharmaCenter. Please DM for business related messages

[iPharma Center @ipharma_center]

SERENA‑6 mostra il valore di una strategia guidata dalla ctDNA nel carcinoma mammario HR+/HER2− avanzato.
https://t.co/a407ZGOb2E
#ASCO26 #TumoreAlSeno #Oncologia #StudiClinici #MedicinaDiPrecisione

[ipharmacenter @ipharmacenter]

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter
Link in the comments
#Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

[iPharma Center @ipharma_center]

A #Pfizer estabelece um novo marco de eficácia a longo prazo no #NSCLC ALK+ com dados de 7 anos do estudo CROWN: impressionantes 55% dos pacientes sem tratamento prévio continuam vivos e sem progressão com #Lorbrena (#lorlatinib). https://t.co/a407ZGOb2E
#ASCO26 #notícias

[ipharmacenter @ipharmacenter]

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter
Link in the comments
#Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

[iPharma Center @ipharma_center]

#Pfizer establishes a long-term efficacy benchmark in ALK+ #NSCLC with landmark 7-year CROWN data: an 55% of treatment-naive patients remain alive and progression-free on #Lorbrena https://t.co/2NLo7Bctc2 #ASCO26 #BREAKING #OncoAlert #ASCODailyNews #ASCO2026 #OncologyNews #NEWS

[ipharmacenter @ipharmacenter]

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter
Link in the comments
#Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

[iPharma Center @ipharma_center]

#ASCO26: The Ph3 Successor-2 trial reveals Mezigdomide combination (MeziKd) reduced risk of disease progression or death by 52% in RRMM vs standard care. Median PFS reached 18 mos vs 8.3 mos.
https://t.co/a407ZGOb2E
#ASCO2026 #OncoAlert #ASCODailyUpdates #ASCO26withiPharmacenter

[ipharmacenter @ipharmacenter]

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter
Link in the comments
#Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

[iPharma Center @ipharma_center]

Find all #ASCO26 updates at one place
https://t.co/a407ZGOb2E
#ASCO26 #ASCOUpdate #ASCONews #ASCO26withiPharmaCenter #OncoAlert

[iPharma Center @ipharma_center]

BeOne presented data of Brukinsa at #ASCO26
#ASCO2026 #CancerResearch #Oncology #Hematology #BloodCancer #ClinicalTrials #PrecisionMedicine #CancerImmunotherapy #GlobalHealth #ClinicalOncology #CancerScience #MolecularOncology #PatientCare #MedicalCongress

[ipharmacenter @ipharmacenter]

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter
Link in the comments
#Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

[iPharma Center @ipharma_center]

#BREAKING: Longest next-gen BTK inhibitor follow-up data ever reported in #CLL
SEQUOIA trial delivers 78-month results for #zanubrutinib vs #bendamustine-#rituximab in first-line CLL
https://t.co/a407ZGOb2E
#pharma #ASCO2026 #ASCO26 #Cancer #OncoAlert #ASCO26withiPharmaCenter

[ipharmacenter @ipharmacenter]

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter
Link in the comments
#Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

[iPharma Center @ipharma_center]

Find the list of top #pharmaceutical companies by revenues in 2025
https://t.co/IcmSBpW5hS
#pharma #pharmaceutical #healthcare #globalhealth #lifesciences #news #media #EULAR2026 #ASCo26

[iPharma Center @ipharma_center]

#AstraZeneca’s #Imfinzi Reduces Recurrence Risk in High-Risk NMIBC, Wins #US #FDA Approval
The Phase III POTOMAC trial shows adding Imfinzi to BCG therapy reduced the risk of recurrence or death by 32% in patients with high-risk NMIBC https://t.co/nchgiSgYPa #news #ASCO26 #media

[ipharmacenter @ipharmacenter]

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter
Link in the comments
#Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

[iPharma Center @ipharma_center]

#NovoNordisk at #ECO2026: In the phase 3 OASIS 4 trial of oral #semaglutide 25 mg, 28.8% of adults were “early responders” (≥10% weight loss by week 16), reaching 21.6% weight loss by week 64
https://t.co/na5nqELv0g
#ECO26 #ObesityCare #news #media #innovation #weightmanagement

[iPharma Center @ipharma_center]

Follow last #ECO2026 updates with
@ipharmacenter
#pharma #ECO2026 #ECO26 #news #media #breaking #obesity #EliLilly #innovation #weightloss #Obesitycare $LLY $NVO
#ECO2026

[ipharmacenter @ipharmacenter]

SURMOUNT-MAINTAIN trial evaluated dose adjustments within #Zepbound therapy. Patients who continued on the MTD for an additional year maintained their #weightloss
https://t.co/eN5CbeO4x8
#pharma #ECO2026 #ECO26 #news #media #breaking #obesity #EliLilly #innovation

[iPharma Center @ipharma_center]

Follow last #ECO2026 updates with @ipharmacenter
#pharma #ECO2026 #ECO26 #news #media #breaking #obesity #EliLilly #innovation #weightloss #Obesitycare $LLY $NVO #ECO2026

[ipharmacenter @ipharmacenter]

In the ATTAIN-MAINTAIN study, patients who switched from the maximum tolerated dose of #Wegovy (semaglutide) to #Foundayo largely preserved their earlier weight reduction
https://t.co/eN5CbeO4x8
#pharma #ECO2026 #ECO26 #news #media #breaking #obesity #EliLilly #innovation

[ipharmacenter @ipharmacenter]

In the ATTAIN-MAINTAIN study, patients who switched from the maximum tolerated dose of #Wegovy (semaglutide) to #Foundayo largely preserved their earlier weight reduction
https://t.co/eN5CbeO4x8
#pharma #ECO2026 #ECO26 #news #media #breaking #obesity #EliLilly #innovation

[ipharmacenter @ipharmacenter]

#CMS launched the 10-year #ACCESSModel in Original #Medicare to test outcome-aligned payments and tech-enabled care for high-burden chronic conditions https://t.co/lOXF6vsB6O​
#CMS #Medicare #news #Trump #BreakingNews #Hypertension #Diabetes #Depression #PresidentTrump #media

[iPharma Center @ipharma_center]

#CMS launched ACCESS Model in the #UnitedStates
https://t.co/2210BnD2A0
#pharma #pharmaceutical #Trump #PresidentTrump #Medicaid #Medicare #DigitalHealth #PopulationHealth #USNews #USA

[ipharmacenter @ipharmacenter]

#CMS launched the 10-year #ACCESSModel in Original #Medicare to test outcome-aligned payments and tech-enabled care for high-burden chronic conditions https://t.co/lOXF6vsB6O​
#CMS #Medicare #news #Trump #BreakingNews #Hypertension #Diabetes #Depression #PresidentTrump #media

[iPharma Center @ipharma_center]

Find the latest #China's #pharmaceutical updates like never before on https://t.co/wdTP1q1jn3

[ipharmacenter @ipharmacenter]

#China’s #NMPA has approved #Pfizer’s recombinant mAb #matazisimab as the first prophylactic option for #hemophilia A or B patients ≥12 years with FVIII/IX inhibitors
https://t.co/uZbN8aLciq​
#hemophilia #bleedingdisorders #pharma #HemeTwitter #OncoTwitter #OncoAlert #OncoAlerts

[iPharma Center @ipharma_center]

Follow #SABCS25 and ASH25 on #ipharmacenter for continuous updates
https://t.co/jr5sYZhYPf
#pharma #pharmaceutical #healthcare #globalhealth #cancer #oncology #cancerresearch #OncoTwitter #OncoAlerts #OncoAlert #CancerAwareness #conferences #Oncology

[ipharmacenter @ipharmacenter]

Find the list of top #pharmaceutical companies by revenues in 2025
https://t.co/R1j2nd53jX
#pharma #pharmaceutical #trump #presidenttrump #Medicare #Medicaid #CMS #healthcare #neurology #oncology #rheumatology #SABCS25 #news #media #top10

[iPharma Center @ipharma_center]

Follow #SABCS25 and ASH25 on #ipharmacenter for continuous updates
https://t.co/jr5sYZhYPf
#pharma #pharmaceutical #healthcare #globalhealth #cancer #oncology #cancerresearch #OncoTwitter #OncoAlerts #OncoAlert #CancerAwareness #conferences #Oncology

[ipharmacenter @ipharmacenter]

#Imfinzi + FLOT is now FDA-approved as the first perioperative #immunotherapy for resectable stage II–IVA gastric and GEJ cancers, based on positive MATTERHORN data
https://t.co/Z429ApBtF8​
#news #media #gastriccancer #GEJcancer #Immunotherapy #OncoTwitter #OncoAlert #OncoAlerts

[iPharma Center @ipharma_center]

Follow #SABCS25 and ASH25 on #ipharmacenter for continuous updates
https://t.co/jr5sYZhYPf
#pharma #pharmaceutical #healthcare #globalhealth #cancer #oncology #cancerresearch #OncoTwitter #OncoAlerts #OncoAlert #CancerAwareness #conferences #Oncology

[ipharmacenter @ipharmacenter]

Follow #SABCS25 and ASH25 on #ipharmacenter for continuous updates
https://t.co/w2L1RabvYo

[iPharma Center @ipharma_center]

#pharma #pharmaceutical #breaking #healthcare #ESMO25 #ASMO25 #SABCS25 #news #media #globalhealth #healthcare #trump

[ipharmacenter @ipharmacenter]

Find the list of top #pharmaceutical companies by revenues in 2025
https://t.co/R1j2nd53jX
#pharma #pharmaceutical #trump #presidenttrump #Medicare #Medicaid #CMS #healthcare #neurology #oncology #rheumatology #SABCS25 #news #media #top10